Vasculonics Inc.

Indianapolis, IN

UEI
KASJGN8XW8P8
CAGE
7XC56
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1800 N Capitol Ave Fl 5, Indianapolis, IN 46202, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Preclinical development of a novel disease modifying therapy for pulmonary arterial hypertension R33HL154135 National Heart Lung and Blood Institute (NIH) $2,033,325
A potential ddah-biotherapeutic to preserve kidney function in cardiac surgery patients R43DK125142 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $234,366
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension. R44HL149496 National Heart Lung and Blood Institute (NIH) $6,863,364
A novel disease modifying therapy for progression of pulmonary arterial hypertension R43HL149496 National Heart Lung and Blood Institute (NIH) $211,943

Similar vendors

Vendor Location Primary NAICS
Covenant Therapeutics LLC UEI KKJLPNVZZWT2 Charlottesville, VA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Adepthera LLC UEI QDWUGUNKHMT5 Palo Alto, CA 325412 Pharmaceutical Preparation Manufacturing
Cornovus Pharmaceuticals Inc. UEI EBD9Y2Q2JW55 New Haven, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
3DT Holdings, LLC UEI E527XPXM1CJ7 San Diego, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Artiam Bio Inc. UEI FKJAXBQEDUJ8 Cary, NC 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Vasculonics Inc. is a minority-owned, self-certified small disadvantaged business registered as a corporate entity to receive federal awards. It has been registered in SAM.gov since July 2017, with a current registration set to expire in April 2025.

Vasculonics Inc. has received three prime federal grant awards from the Department of Health and Human Services' National Institutes of Health. The largest award, valued at over $2 million, was granted by the National Heart, Lung, and Blood Institute for the preclinical development of a novel disease-modifying therapy for pulmonary arterial hypertension. Another award from the same institute, worth around $212,000, funded research on a potential therapy for the progression of pulmonary arterial hypertension. The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vasculonics Inc. a $234,000 grant to investigate a potential DDAH-biotherapeutic for preserving kidney function in cardiac surgery patients. These awards highlight Vasculonics Inc.'s focus on developing novel therapies for cardiovascular and pulmonary conditions, with a particular emphasis on hypertension and kidney-related complications.

Quick answers

Is Vasculonics Inc. registered in SAM.gov?

Yes. Vasculonics Inc.'s SAM.gov registration is active through February 1, 2027.

What is Vasculonics Inc.'s most recent federal award?

Vasculonics Inc.'s most recent federal grant award is Preclinical development of a novel disease modifying therapy for pulmonary arterial hypertension (R33HL154135), from National Heart Lung and Blood Institute (NIH), on September 15, 2020.

On GovTribe

See Vasculonics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login